Preliminary results from Phase IIb study of BI 201335 and BI 207127 (Boehringer) show positive response in Hepatitis C patients

New preliminary results from the SOUND-C3 trial, Boehringer Ingelheim's investigational Interferon-free regimen which combines BI 201335 (faldaprevir) and BI 207127, show that 100 percent (n=20) of patients with Hepatitis C GT-1b achieved sustained virologic response four weeks (SVR4) after completing a 16 week course of treatment. Two patients experienced serious adverse events and two patients discontinued treatment early due to adverse events in SOUND-C3. Four patients in this study had compensated liver cirrhosis (damaged or scarred liver tissue).

These data further support the trial design for Boehringer Ingelheim's pivotal HCVerso study, a Phase III trial of the drug combination which has just started enrollment. Full results from SOUND-C3 are expected in 2013.